Cancer Chemotherapy and Pharmacology

, Volume 64, Issue 1, pp 27–33

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

  • Sun Jin Sym
  • Dae Ho Lee
  • Hye Jin Kang
  • Seung Hyun Nam
  • Ho Young Kim
  • Seok Jin Kim
  • Hyeon Seok Eom
  • Won Seog Kim
  • Cheolwon Suh
Original Article

DOI: 10.1007/s00280-008-0847-y

Cite this article as:
Sym, S.J., Lee, D.H., Kang, H.J. et al. Cancer Chemother Pharmacol (2009) 64: 27. doi:10.1007/s00280-008-0847-y

Abstract

Purpose

We investigated the efficacy and toxicity of the etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx), in which oxaliplatin (Ox) was substituted for cisplatin in the ESHAP [etoposide (E), methylprednisolone (S), high-dose cytarabine (HA), and cisplatin (P)] regimen, for patients with refractory/relapsed aggressive non-Hodgkin’s lymphoma (NHL).

Materials and methods

The ESHAOx consisted of E (40 mg/m2 on days 1–4), S (500 mg on days 1–5), HA (2 g/m2 on day 5), and Ox (130 mg/m2 on day 1) every 3 weeks to a maximum of six cycles. Responses were assessed every three cycles.

Results

Twenty-seven patients were enrolled (19 with relapsed and 8 with refractory; 10 with an IPI score of 3–5). The overall response rate was 63% [95% confidence interval (95% CI) 45–81%], including eight complete remissions (CR) and one unconfirmed CR (33%). The median duration of response was 9.9 months (95% CI 5.7–14.2 months). After a median follow-up of 18.6 months, the median progression-free and overall survival was 5.3 months (95% CI 3.9–6.7 months) and 15.1 months (95% CI 9.4–20.9 months), respectively, with a 1-year survival rate of 61.5%. Most common grade 3/4 hematologic toxicities were neutropenia (56%) and thrombocytopenia (35%), whereas no patient experienced grade 3/4 renal or neurotoxicity.

Conclusion

The efficacy and toxicity profiles suggested that the ESHAOx can be an alternative option for patients with refractory/relapsed aggressive NHL.

Keywords

OxaliplatinLymphomaSalvage therapyChemotherapy

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sun Jin Sym
    • 1
    • 8
  • Dae Ho Lee
    • 1
  • Hye Jin Kang
    • 2
  • Seung Hyun Nam
    • 3
  • Ho Young Kim
    • 4
  • Seok Jin Kim
    • 5
  • Hyeon Seok Eom
    • 6
  • Won Seog Kim
    • 7
  • Cheolwon Suh
    • 1
  1. 1.Department of Internal MedicineAsan Medical Center, University of Ulsan College of MedicineSeoulSouth Korea
  2. 2.Department of MedicineKorea Institute of Radiological and Medical SciencesSeoulSouth Korea
  3. 3.Department of Internal MedicineSeoul Veterans HospitalSeoulSouth Korea
  4. 4.Department of Internal Medicine, Sacred Heart HospitalCollege of Medicine, Hallym UniversityAnyangSouth Korea
  5. 5.Department of Internal MedicineCollege of Medicine, Korea UniversitySeoulSouth Korea
  6. 6.Hematology–Oncology Clinic, Research Institute and HospitalNational Cancer CenterGoyangSouth Korea
  7. 7.Department of Medicine, Samsung Medical CenterSchool of Medicine, Sungkyunkwan UniversitySeoulSouth Korea
  8. 8.Department of Internal MedicineGachon University Gil HospitalIncheonSouth Korea